Holen Sie sich die Stockscreener-App
4.09
3.99%
-0.17
Handel nachbörslich:
4.00
-0.09
-2.20%
Opus Genetics Inc Aktie (IRD) Neueste Nachrichten
Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst - Yahoo Finance
Leerink Partners initiates coverage of Opus Genetics (IRD) with outperform recommendation - MSN
IRD Initiates Coverage by Leerink Partners -- Rating 'Outperform' - GuruFocus
Leerink Partners Initiates Opus Genetics at Outperform With $10 Price Target - Moomoo
Leerink initiates Opus Genetics stock with outperform rating - Investing.com
Leerink initiates Opus Genetics stock with outperform rating By Investing.com - Investing.com Canada
Foundation Fighting Blindness Retinal Degeneration Fund Sells 1, - GuruFocus
Foundation fighting blindness fund sells $7.4m of Opus Genetics (IRD) stock - Investing.com
Opus Genetics (IRD) investor files exit 13D after stake falls under 5% - Stock Titan
Foundation Fighting Blindness fund trims Opus Genetics (IRD) stake with 1.7M-share sale - Stock Titan
Opus Genetics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
IRD: Gene therapy pipeline advances with pivotal data and regulatory milestones expected in 2024 - TradingView
Lifesci Capital Predicts Lower Earnings for Opus Genetics - MarketBeat
Opus Genetics, Inc. (IRD) reports Q1 loss, misses revenue estimates - MSN
Opus Genetics (NASDAQ:IRD) Cut to Sell at Wall Street Zen - MarketBeat
Nantahala Capital (IRD) reports 4.84M shares; 3.16M exercisable within 60 days - Stock Titan
Perceptive (IRD) group holds 9.99% of Opus Genetics; warrants capped by limit - Stock Titan
Caligan Partners reports 8.5% stake in Opus Genetics (IRD) - Stock Titan
HC Wainwright Lifts Earnings Estimates for Opus Genetics - MarketBeat
Balyasny holds 5.11M shares in Opus Genetics (NASDAQ: IRD), includes warrants - Stock Titan
Cantor Fitzgerald Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Opus Genetics (IRD) Projected to Post Quarterly Earnings on Thursday - MarketBeat
A Quick Look at Today's Ratings for Opus Genetics(IRD.US), With a Forecast Between $8 to $11 - Moomoo
IRD Maintained by Citizens -- Price Target Lowered to $11.00 - GuruFocus
Opus Genetics (IRD) Schedule 13G/A: Bios-affiliated funds report 4.53% stake - Stock Titan
Adage Capital (IRD) discloses 8.47% stake in Opus Genetics — 6,029,775 shares - Stock Titan
Chardan Capital Maintains Opus Genetics(IRD.US) With Buy Rating, Raises Target Price to $11 - Moomoo
Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference - The Manila Times
Citizens cuts Opus Genetics stock price target on share dilution By Investing.com - Investing.com Canada
Opus Genetics (IRD) Q1 Loss Of US$65.5 Million Intensifies Bearish Community Narratives - Sahm
Is Opus Genetics (IRD) 979.2% Overvalued After Q1 2026? EPS ($0. - GuruFocus
TradingKey - TradingKey
Opus Genetics (IRD) Q1 2026 results show large non-cash loss but stronger cash runway - Stock Titan
Opus Genetics 1Q License & Collaborations Rev Rev $2.2M >IRD - Moomoo
Opus Genetics (IRD) Reports Q1 Revenue Below Expectations - GuruFocus
Opus Genetics 1Q Loss/Shr 75c >IRD - Moomoo
Opus Genetics Reports Q1 2026 Results, Advances Gene Therapy Pipeline for Inherited Retinal Diseases and Secures Funding Through 2029 12 - Minichart
Opus Genetics Releases Q1 2026 Financial Results - AlphaStreet
Opus Genetics earnings missed by $0.62, revenue fell short of estimates - Investing.com Canada
Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update - The Manila Times
Opus Genetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Opus Genetics (Nasdaq: IRD) posts Q1 2026 loss, extends cash runway into 2029 - Stock Titan
Presbyopia Market to Witness Accelerated Growth at a CAGR of 4.9% During the Forecast Period (2026–2036) Supported by Expanding Treatment Landscape | DelveInsight - GlobeNewswire Inc.
Opus Genetics Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
MSN Money - MSN
LifeSci Capital Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Opus Genetics Inc. (IRD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
LifeSci Capital Maintains Opus Genetics(IRD.US) With Buy Rating, Raises Target Price to $10 - Moomoo
Piper Sandler Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study - markets.businessinsider.com
Opus Genetics reports vision improvements in gene therapy trials - Investing.com
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):